Third heart sound and elevated jugular venous pressure as markers of the subsequent development of heart failure in patients with asymptomatic left ventricular dysfunction - 28/08/11
, J.Eduardo Rame, MD, MPhil a, Daniel L Dries, MD, MPH a, bAbstract |
Purpose |
To determine the independent prognostic value of a third heart sound (S3) and elevated jugular venous pressure in patients with asymptomatic left ventricular dysfunction.
Methods |
We performed a post hoc analysis of 4102 participants from the Studies of Left Ventricular Dysfunction (SOLVD) prevention trial. In that trial, participants with asymptomatic or minimally symptomatic left ventricular dysfunction (New York Association class I or II, left ventricular ejection fraction ≤0.35, no treatment for heart failure) were allocated randomly to enalapril or placebo and followed for a mean (± SD) of 34 ± 14 months. The presence of an S3 and elevated jugular venous pressure was ascertained by physical examination at study enrollment. We used multivariate proportional hazards models to determine whether these physical examination findings were associated with the development of heart failure, a prespecified endpoint of the SOLVD prevention trial.
Results |
At baseline, 209 subjects (5.1%) had an S3 and 70 (1.7%) had elevated jugular venous pressure. Heart failure developed in 1044 subjects (25.5%). After adjusting for other markers of disease severity, an S3 was associated with an increased risk of heart failure (relative risk [RR] = 1.38; 95% confidence interval [CI]: 1.09 to 1.73; P = 0.007) and the composite endpoint of death or development of heart failure (RR = 1.34; 95% CI: 1.09 to 1.64; P = 0.005). Elevated jugular venous pressure was also associated with these outcomes in multivariate models.
Conclusion |
The physical examination provides prognostic information among patients with asymptomatic or minimally symptomatic left ventricular dysfunction.
El texto completo de este artículo está disponible en PDF.Keywords : Heart sounds, Physical examination, Jugular veins, Heart failure, Heart auscultation
Esquema
 | Drs. Drazner, Rame, and Dries received support from the Donald W. Reynolds Cardiovascular Clinical Research Center, Dallas, Texas. Dr. Drazner was the recipient of a Doris Duke Clinical Scientist Development Award from the Doris Duke Charitable Foundation, New York, New York. The National Heart, Lung, and Blood Institute, Bethesda, Maryland, sponsored the Studies of Left Ventricular Dysfunction (SOLVD) prevention trial. Merck, Whitehouse Station, New Jersey, supplied the study drug for the SOLVD prevention trial. |
Vol 114 - N° 6
P. 431-437 - avril 2003 Regresar al número
- Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women
- Aruna D Pradhan, JoAnn E Manson, James B Meigs, Nader Rifai, Julie E Buring, Simin Liu, Paul M Ridker
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?